Die Grenzen der Wunderheiler ,ZDF 22.15

Thema bewerten
Beiträge: 12
Zugriffe: 5.759 / Heute: 2
Osiris Therapeutic. kein aktueller Kurs verfügbar
 
DasMünz:

Die Grenzen der Wunderheiler ,ZDF 22.15

3
06.12.06 19:23
Joachim Bublath
                    Â§
Joachim Bublath
                    Â§
                    Â§
Stammzellen gelten als Heilsbringer der Zukunft: Sie sollen unheilbar Kranken wieder ein normales Leben ermöglichen. Doch hierzulande zerbrechen sich die Forscher über das Potenzial und die Gefahren von Stammzellen den Kopf. Denn die Alleskönner werden aus Embryonen gewonnen - ein gewaltiges ethisches Problem.

"Die Grenzen der Wunderheiler"
am 6. Dezember 2006, 22:15 Uhr  
>3x bewertet

Werbung

Entdecke die beliebtesten ETFs von SPDR

SPDR MSCI Europe Financials UCITS ETF
Perf. 12M: +27,55%
SPDR MSCI Europe Communication Services UCITS ETF
Perf. 12M: +23,67%
SPDR MSCI Europe Utilities UCITS ETF
Perf. 12M: +22,84%
SPDR S&P U.S. Utilities Select Sector UCITS ETF
Perf. 12M: +22,55%
SPDR MSCI World Utilities UCITS ETF
Perf. 12M: +20,07%

DasMünz:

vom 6.11.06

 
06.12.06 19:26
Hot Stocks Investor - Osiris Therapeutics Fuß in die Tür stellen

10:28 06.11.06

Endingen (aktiencheck.de AG) - Die Experten von "Hot Stocks Investor" raten bei der Aktie von Osiris Therapeutics (ISIN US68827R1086/ WKN A0KF3R) einen Fuß in die Tür zu stellen.

Wie die Analysten von Jefferies in einer sehr spannenden aktuellen Researchnote festhalten würden, sei Osiris der einzige Stammzellenforscher, der bereits ein Präparat am Markt habe. Das sei bislang nur deshalb weniger aufgefallen, weil der Marktstart von Osteocel für Knochenwachstum nach chirurgischen Eingriffen noch vor dem Börsengang der Gesellschaft im August stattgefunden habe und an der Börse entsprechend wenig wahrgenommen worden sei.

Wie es aussehe, sei Osiris aber drauf und dran, diese fast avantgardische Stellung noch weiter auszubauen. So habe man mit Prochymal ein weiteres Produkt in der Pipeline, nämlich ein ebenfalls stammzellenbasiertes Therapeutikum, dass momentan in Phase III-Tests gegen Morbus Crohn sowie die so genannte Graft-versus-Host-Disease zum Einsatz kommen solle. Dabei handle es sich um eine höchst problematische immunologische Reaktion, die bei einer Knochenmark- und Stammzellentransplantation auftrete und erhebliche Komplikationen auslösen könne. Sollte sich Prochymal in den laufenden Tests weiter als zuverlässig und erfolgreich erweisen, würde Osiris die Rekordstellung in der Stammzellentherapie weiter eindrucksvoll ausbauen können. Prochymal wäre nämlich das erste Stammzellenpräparat in seiner Kategorie, das von der FDA eine Zulassung erhalten würde.

Das ist für die Experten von "Hot Stocks Investor" ein guter Grund bei der Osiris Therapeutics-Aktie perspektivisch einen Fuß in der Tür zu haben.
(06.11.2006/ac/a/a)  
Bewerten
DasMünz:

Gute Neuigkeiten

 
11.12.06 16:56
Osiris Therapeutics, Inc. (NASDAQ:OSIR) announces follow-on data for its ongoing Phase II trial evaluating PROCHYMAL for the treatment of acute Graft vs. Host Disease. The study found that patients were twice as likely to have total clinical resolution of their disease when PROCHYMAL was added to steroid therapy, compared to reported results for steroids alone. Furthermore, patients experiencing this complete response had a survival rate of over 90% at day 120. The data will be featured during a poster presentation at the 48th Annual Meeting of the American Society of Hematology.

Anzeige:

Graft vs. Host Disease or GVHD is a life threatening immunological reaction that occurs in certain patients who have received a bone marrow transplant. GVHD is a form of rejection in which immune cells from the donated bone marrow attack the recipient's own organs and tissues. There are no approved treatments for GVHD. As a result, it is one of the leading causes of death in bone marrow transplant patients.

The Phase II trial is a randomized, prospective, open label trial, being conducted at 16 leading cancer centers in the US. In addition to standard care including steroids, patients were given two infusions of PROCHYMAL, three days apart at the onset of moderate to severe (grades II-IV) GVHD. Endpoints of the study include response of GVHD to treatment with PROCHYMAL, survival, and the safety and tolerability of the drug.

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
DasMünz:

News und neues Jahrenhoch

 
15.12.06 17:12
Osiris Therapeutics, Inc. (NASDAQ:OSIR) and AlloSource announced today that they have reached a multi-year agreement for the supply of orthopedic tissue. Under the terms of the agreement, AlloSource commits to provide bone matrix to Osiris for use in the production of its Osteocel product line. AlloSource is one of the nation's largest non-profit providers of bone and soft tissue allografts for use in surgical procedures, as well as allograft skin for burn applications.

Anzeige:

Osteocel is the first product containing viable stem cells to be offered for the repair, replacement or reconstruction of bone defects. Osiris leveraged its extensive stem cell experience and intellectual property in the formulation of the product. Following nearly 12 years of research and development, Osteocel was launched in July of 2005. The product is used as an alternative to autograft, a term referring to the use of a patient's own bone during orthopedic surgery. Osteocel helps avoid the complication rates associated with autograft usage, which can be as high as 35%.

Founded in 1994 and based in Centennial, Colorado, AlloSource continues to increase the availability of high quality, safe allografts to save and improve lives of people in its local donor communities. AlloSource was one of the first national tissue networks to have all facets of bone and tissue recovery, processing and distribution accredited by the American Association of Tissue Banks (AATB).

"We are pleased to be partnered with AlloSource, one of the most trusted providers of allograft tissue in the United States," said C. Randal Mills, Ph.D., President and CEO of Osiris. "This agreement serves to increase our capacity to produce Osteocel, but most importantly, it puts patient safety first."

To ensure that the technology is made available to the communities from which it is sourced, the agreement enables AlloSource to act as a non-exclusive distributor of Osteocel in AlloSource's local donor communities. Osiris will continue to be the sole manufacturer of the product.

"AlloSource is committed to providing safe, quality tissue to our local communities," said Tom Cycyota, President and CEO of AlloSource. "This arrangement leverages the strengths of both organizations to bring the exciting Osteocel technology to more patients in our communities and across the country."
Bewerten
DasMünz:

-8 % Herabstufung

 
03.01.07 17:39
Rating-Update:

New York (aktiencheck.de AG) - Die Analysten von Jefferies & Co stufen die Aktie von Osiris Therapeutics (ISIN US68827R1086/ WKN A0KF3R) von "buy" auf "hold" herab. Das Kursziel sehe man bei 24 USD. (03.01.2007/ac/a/u)
Bewerten
 
09.01.07 19:16


Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that PROCHYMAL(TM) has received Fast Track designation from the U.S. Food and Drug Administration, expediting the development of the stem cell treatment for Crohn's Disease that does not respond to standard therapies. Additionally, Osiris has received clearance to conduct a Phase III clinical trial using PROCHYMAL to treat this resistant form of Crohn's Disease. The Phase III program was developed in consultation with FDA, and if successful, will be the last phase of testing before the company seeks full approval for Crohn's Disease.



Osiris recently reported positive clinical trial results evaluating PROCHYMAL for treatment resistant Crohn's Disease and Graft versus Host Disease, or GVHD. In a Phase II study of PROCHYMAL for the treatment of patients with moderate to severe Crohn's Disease who had failed to respond to standard therapies, every patient evaluated experienced a reduction in Crohn's Disease Activity Index or CDAI, signifying a reduction in the disease severity. There was a statistically significant decrease in average CDAI scores of 105 points from 341 to 236 by day 28 (p=0.004). In a Phase II study of PROCHYMAL for the treatment of acute GVHD, 94% of evaluable patients responded after receiving two infusions of PROCHYMAL. The study found that patients were twice as likely to have total clinical resolution of their disease when PROCHYMAL was added to steroid therapy, compared to reported results for steroids alone.

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
DasMünz:

ATH über 28 Dollar

 
10.01.07 20:04
und der Dollar steigt auch
Bewerten
DasMünz:

Osiris Therapeutics Has Risen To A New High

 
10.01.07 20:20
 IPO ALERT - Osiris Therapeutics Has Risen To A New High

(RTTNews) - Osiris Therapeutics has run up to a new historic high by posting steady gains over the course of Wednesday's session. Shares are up $.156 at $28.20, with volume on the rise.

Osiris Therapeutics began trading on August 21, 2006 at an IPO price of $10.00.
Bewerten
Anzeige: Ist das der Durchbruch für den KI-Biotech-Geheimtipp?

Potenzial riesig, Aktie günstig!
DasMünz:

+22% was ist denn heute los ? o. T.

 
22.03.07 20:18
Bewerten
DasMünz:

Good News +16%

 
26.03.07 17:23
Osiris Therapeutics, Inc. (Nasdaq:OSIR) today announces positive six-month results in a groundbreaking clinical trial evaluating PROVACEL(TM), an adult mesenchymal stem cell (MSC) therapy for the treatment of heart disease.


In a 53-patient, double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of the intravenous administration of PROVACEL, heart attack patients receiving the therapy had significantly lower rates of adverse events, such as cardiac arrhythmias, as well as significant improvements in heart, lung and overall condition. Joshua Hare M.D., the trial's lead investigator, presented the data this morning at the American College of Cardiology's Innovation in Intervention: i2 Summit.

"We are extremely enthusiastic and encouraged by the degree to which these results indicate that MSCs are not only safe, but also appear to clinically improve patients who have suffered a heart attack," said Dr. Hare, who is the Lemberg Professor of Medicine at the Miller School of Medicine, University of Miami; Chief of the Cardiology Division; and Director of the School's Interdisciplinary Stem Cell Institute. "The results consistently show patient improvement with regard to heart and lung function, and indicate global improvements in well-being. These findings strongly support the ongoing development of PROVACEL for acute myocardial infarction and possibly other forms of heart and lung disease."

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
DasMünz:

OSIR huscht auf 12- Monatshoch

 
16.08.08 22:01
Die Grenzen der Wunderheiler ,ZDF 22.15 180557
Bewerten
DasMünz:

jetzt fast bei 20$

 
24.09.08 20:35
Bewerten
Es gibt keine neuen Beiträge.
 Ich: 


Börsen-Forum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen

Neueste Beiträge aus dem Osiris Therapeutics Forum

Wertung Antworten Thema Verfasser letzter Verfasser letzter Beitrag
  42 OSIRIS therapeutics Chalifmann3 Vassago 25.04.21 02:19
  8 Aus Verbundenheit wilhelmo1 wilhelmo1 08.02.17 21:45
3 11 Die Grenzen der Wunderheiler ,ZDF 22.15 DasMünz DasMünz 24.09.08 20:35
    OSIRIS Therapeutics DasMünz   04.12.06 19:20